Affiliation:
1. University Hospital Bonn: Universitatsklinikum Bonn
2. Medical University of Graz: Medizinische Universitat Graz
3. Immanuel Krankenhaus Berlin
4. Freiburg University Hospital: Albert-Ludwigs-Universitat Freiburg Universitatsklinikum Freiburg
Abstract
Abstract
• Background:
Glucocorticoids (GC) are the standard treatment for giant cell arteritis (GCA), even though they are associated with adverse side effects and high relapse rates. Tocilizumab (TCZ), an interleukin-6 receptor antagonist, has shown promise in sustaining remission and reducing the cumulative GC dosage, but it increases the risk of infections and is expensive. After discontinuation of TCZ, only about half of patients remain in remission. Additionally, only few studies have been conducted looking at remission maintenance, highlighting the need for alternative strategies to maintain remission in GCA. Methotrexate (MTX) has been shown to significantly decrease the risk of relapse in new-onset GCA and is already a proven safe drug in many rheumatologic diseases.
• Methods:
This study aims to evaluate the efficacy and safety of MTX in maintaining remission in patients with GCA who have previously been treated with GC and at least six months with TCZ. We hypothesise that MTX can maintain remission in GCA patients, who have achieved stable remission after treatment with GC and TCZ, and prevent the occurrence of relapses. The study design is a monocentric, randomised, double-blind, placebo-controlled, parallel group phase II trial randomising 40 GCA patients 1:1 into a MTX or placebo arm. Patients will receive 17.5 mg MTX / matching placebo weekly by subcutaneous injection for 12 months, with the possibility of dose reduction if clinically needed. A six-month follow up takes place. The primary endpoint is the time to first relapse in the MTX group versus placebo during the 12-month treatment period. Secondary outcomes include patient- and investigator-reported outcomes and laboratory findings, as well as the prevalence of aortitis, number of vasculitic vessels, and change in intima-media thickness during the study.
• Discussion:
This is the first clinical trial evaluating remission maintenance of GCA with MTX after a previous treatment cycle with TCZ. Following the discontinuation of TCZ in GCA, MTX could be a safe and inexpensive drug.
• Trial registration: ClinicalTrials.gov, NCT05623592. Registered 21.11.2022, https://classic.clinicaltrials.gov/ct2/show/NCT05623592?term=giant+cell+arteriitis&cond=methotrexate&draw=2&rank=1
EU Clinical Trials Register, 2022-501058-12-00
German Clinical Trials Register DRKS00030571
Publisher
Research Square Platform LLC
Reference57 articles.
1. The spectrum of giant cell arteritis and Npolymyalgia rheumatica: revisiting the concept of the disease;Dejaco C;Rheumatology (Oxford),2017
2. Giant Cell Arteritis;Hoffman GS;Ann Intern Med,2016
3. Epidemiology of giant cell arteritis and polymyalgia rheumatica;Gonzalez-Gay MA;Arthritis Rheum,2009
4. Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities;Petri H;Arthritis Care Res (Hoboken),2015
5. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis // The American College of Rheumatology 1990 criteria for the classification of vasculitis;Hunder GG;Introduction Arthritis Rheum,1990
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献